Su Yan-Ye, Chien Chih-Yen, Luo Sheng-Dean, Huang Tai-Lin, Lin Wei-Che, Fang Fu-Min, Chiu Tai-Jan, Chen Yen-Hao, Lai Chi-Chih, Hsu Cheng-Ming, Li Shau-Hsuan
Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Kaohsiung Chang Gung Head and Neck Oncology Group, Cancer Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
World J Surg Oncol. 2016 Mar 22;14:86. doi: 10.1186/s12957-016-0844-2.
Smoking and betel nut chewing are well-known risk factors for head and neck squamous cell carcinoma (HNSCC). Smoking is also a strong prognosticator for patients with locally advanced HNSCC receiving induction chemotherapy. Smoking with or without betel nut chewing is a common practice in Asia. However, little is known regarding whether betel nut chewing can serve as a prognostic factor for smoking patients with locally advanced HNSCC receiving induction chemotherapy. The aim of this study was to evaluate the prognostic impact of betel nut chewing in such patients receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF).
From January 2010 to December 2012, we retrospectively analyzed 162 smoking patients with locally advanced HNSCC who received induction chemotherapy with TPF at our institution. Background characteristics, including a history of betel nut chewing, were analyzed as potential prognostic factors.
Among the 162 smoking patients, 131 patients (81%) were betel nut chewers, while 31 (19%) were non-betel nut chewers. One hundred fifty-six (96%) were men, and 6 (4%) were women. The median age was 53 years. The overall response rates to induction chemotherapy were 57 and 77% in patients with and without betel nut chewing history, respectively (P = 0.038). The 2-year progression survival rates were 37 and 67% in patients with and without betel nut chewing history, respectively (P = 0.004). The 2-year overall survival rates were 47 and 71% in patients with and without betel nut chewing history, respectively (P = 0.017). Betel nut chewing history was independently associated with a poor response to induction chemotherapy, an inferior progression-free survival rate, and a poor overall survival rate.
Our results indicate that betel nut chewing history is independently associated with poor prognosis in smoking patients with locally advanced HNSCC receiving induction chemotherapy with TPF. Further investigation is warranted to explain this effect of betel nut chewing history on these patients' prognosis.
吸烟和嚼槟榔是头颈部鳞状细胞癌(HNSCC)众所周知的危险因素。吸烟也是局部晚期HNSCC患者接受诱导化疗的一个强有力的预后指标。在亚洲,吸烟与否同时嚼槟榔是一种常见的行为。然而,关于嚼槟榔是否可作为接受诱导化疗的吸烟局部晚期HNSCC患者的一个预后因素,人们知之甚少。本研究的目的是评估嚼槟榔对接受多西他赛、顺铂和氟尿嘧啶(TPF)诱导化疗的此类患者的预后影响。
2010年1月至2012年12月,我们回顾性分析了162例在本机构接受TPF诱导化疗的吸烟局部晚期HNSCC患者。分析包括嚼槟榔史在内的背景特征作为潜在的预后因素。
在162例吸烟患者中,有131例(81%)嚼槟榔,31例(19%)不嚼槟榔。156例(96%)为男性,6例(4%)为女性。中位年龄为53岁。有和无嚼槟榔史的患者诱导化疗的总缓解率分别为57%和77%(P = 0.038)。有和无嚼槟榔史的患者2年无进展生存率分别为37%和67%(P = 0.004)。有和无嚼槟榔史的患者2年总生存率分别为47%和71%(P = 0.017)。嚼槟榔史与诱导化疗反应差、无进展生存率低和总生存率低独立相关。
我们的结果表明,嚼槟榔史与接受TPF诱导化疗的吸烟局部晚期HNSCC患者预后不良独立相关。有必要进一步研究以解释嚼槟榔史对这些患者预后的这种影响。